financetom
Business
financetom
/
Business
/
SocGen Comments on Brazil Central Bank's Surprise Rate Hike This Week
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SocGen Comments on Brazil Central Bank's Surprise Rate Hike This Week
Jun 20, 2025 5:19 AM

08:02 AM EDT, 06/20/2025 (MT Newswires) -- Brazil's central bank (BCB) unexpectedly raised the policy rate by 25bps to 15.0% on Wednesday, noted Societe Generale.

The BCB also signaled a pause in its tightening cycle to evaluate the cumulative impact of past hikes, but warned it is prepared to raise rates further if necessary, wrote the bank in a note to clients.

The decision, along with the hawkish statement, reinforces the BCB's inflation-fighting credibility, stated SocGen.

The bank believes the easing cycle will get underway in Q1 2026. Given the hawkish statement, SocGen raised its Selic rate projections for the forecast horizon, expecting year-end rates in 2026 and 2027 to reach 12.25% and 10.25%, respectively, compared with their earlier projections of 11.75% and 9.75%.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--CSW Industrials Raises Quarterly Dividend to $0.24 a Share, Payable Nov. 8 to Shareholders of Record as of Oct. 25
--CSW Industrials Raises Quarterly Dividend to $0.24 a Share, Payable Nov. 8 to Shareholders of Record as of Oct. 25
Oct 11, 2024
08:49 AM EDT, 10/11/2024 (MT Newswires) -- Price: 374.45, Change: +0.06, Percent Change: +0.02 ...
Acrivon Therapeutics Reports First Patient Dosed in Phase 1 Trial of ACR-2316
Acrivon Therapeutics Reports First Patient Dosed in Phase 1 Trial of ACR-2316
Oct 11, 2024
08:50 AM EDT, 10/11/2024 (MT Newswires) -- Acrivon Therapeutics ( ACRV ) said Friday that the first patient has been dosed in its phase 1 clinical trial evaluating ACR-2316, which is being developed to treat patients with solid tumors. The company said the trial will determine the maximal tolerated dose and recommended phase 2 monotherapy dose, characterization of the pharmacokinetic...
Moody's cuts Volkswagen's outlook to 'negative' due to operating weakness
Moody's cuts Volkswagen's outlook to 'negative' due to operating weakness
Oct 11, 2024
FRANKFURT (Reuters) - Rating agency Moody's has cut its outlook on Volkswagen to negative from stable, citing a deteriorating operating performance at Europe's top carmaker and expected challenges to turn the situation around. We expect VW's operating performance to be muted into 2025 driven by low volume growth globally including a weak domestic China and sluggish Western Europe, increasing price...
Gannett Reports Results of Early Participation in 2026 Notes Exchange Offer
Gannett Reports Results of Early Participation in 2026 Notes Exchange Offer
Oct 11, 2024
08:49 AM EDT, 10/11/2024 (MT Newswires) -- Gannett ( GCI ) on Friday reported the results of early participation in an exchange offer for holders of its outstanding 6% senior secured notes due 2026. The company said that at as of the early tender time of 5 pm ET on Thursday, about $40.4 million of the notes have been tendered...
Copyright 2023-2026 - www.financetom.com All Rights Reserved